StreetInsider.com News Articles

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

Avere Therapeutics, Inc., a privately held biotechnology company, has announced a $500 million private placement from a syndicate of institutional healthcare investors to support the development of AVR-001, a once-weekly oral IL-23 receptor antagonist.

The placement consists of common stock and pre-funded warrants. Participants include Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, RTW Investments, Eventide Asset Management, BB Biotech, Sirenia Capital Management LP, ADAR1 Capital Management, Wellington Management, Janus Henderson Investors, and other institutional investors.

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics raises $500M in private placement for drug program

Mon, 10 Aug 2026 07:01:11 -0400

The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Mon, 10 Aug 2026 07:00:00 -0400

Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001

Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029

SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Avere Therapeutics, Inc. ("Avere" or the "Company"), a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, today announced a $500 million private placement (the "Private Placement") from a syndicate of leading healthcare investors. The Private Placement is in addition to the previously announced $320 million concurrent private

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Mon, 10 Aug 2026 07:00:00 -0400

Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001

Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Mon, 10 Aug 2026 07:00:00 -0400

Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001

Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Mon, 10 Aug 2026 07:00:00 -0400

Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001

Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Mon, 10 Aug 2026 07:00:00 -0400

Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001

Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Mon, 10 Aug 2026 07:00:00 -0400

Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001

Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029